Bifidobacterium lactis for Health & Longevity - Quick Reference Sheet

Bifidobacterium lactis for Health & Longevity

Created on 09/05/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A live gut bacterium taken daily, as a capsule or inside fermented dairy. What it does depends on which commercial version a product contains. The strongest signal is on bowel function; findings on gut pain, milk sugar digestion, gum bleeding, nasal allergy, sleep and blood sugar are isolated. Harms are mostly gas and bloating. Much evidence is company-produced. (Full Review)

Protocol

Standard daily dose
1 to 20 billion
Colony-forming units daily. Dose-ranging work found effect rising with dose from 1.8 to 17.2 billion.
Targeted single-strain approach
One strain per endpoint
One trialled strain is used for one endpoint, following the model of the ingredient houses that developed the trialled strains.
Best time of day
With a meal
Most trials dosed once daily with a meal. Food buffers stomach acid, so with-meal dosing is the defensible default.
Time to effect
Bowel transit
Within 14 days
Transit changes appeared within 14 days in the dose-ranging trial.
Abdominal pain in irritable bowel syndrome
6 weeks
Pain and overall symptom severity separated from placebo over six weeks.
Immune markers
3 to 6 weeks
Anything requiring longer than eight weeks to appear is not supported by the trial timelines.

Benefits

Contraindications
  • Central venous catheter or other indwelling intravascular line
  • Neutropenia (absolute neutrophil count below 500 cells per microlitre)
  • Solid-organ or bone-marrow transplant within 100 days, or while on anti-rejection therapy
  • Immunosuppressants (tacrolimus, ciclosporin, mycophenolate) while immunosuppression is profound
  • Cytotoxic chemotherapy during neutropenic windows
  • Short bowel syndrome (under 200 cm of residual small intestine)
  • Predicted severe acute pancreatitis (APACHE II score 8 or above)
  • Critically ill patients receiving mechanical ventilation, outside a supervised trial protocol
  • Extremely preterm infants, born before 28 weeks, outside a neonatal unit's own supervised protocol
Key Interactions
  • Oral antibiotics (amoxicillin-clavulanate, azithromycin, doxycycline)
  • Stomach-acid blockers, sold over the counter (omeprazole, esomeprazole, lansoprazole)
  • Anti-diarrhoea medicines, sold over the counter (loperamide, bismuth subsalicylate)
  • Prebiotic fibre supplements (inulin, polydextrose, galacto-oligosaccharides)
  • Osmotic and bowel-stimulating supplements (magnesium citrate, magnesium oxide, high-dose vitamin C)
  • Cholesterol-lowering supplements (plant sterols, red yeast rice, soluble fibre)
  • Other live-organism interventions (fermented foods, multi-strain products, faecal microbiota transplantation)

Risk & Side Effects

  • High: Gas, bloating and abdominal discomfort
  • Medium: Unfavourable shift in blood lipids
  • Low: Bloodstream infection in compromised hosts; symptom worsening with small intestinal bacterial overgrowth
  • Speculative: Blunted microbiome recovery after antibiotics; transfer of antibiotic resistance genes

Monitoring

Marker Target Why
Complete spontaneous bowel movements per week 5 to 14 Primary endpoint; the outcome with the strongest evidence
Bristol Stool Form Scale score Types 3 to 4 Captures consistency, which moves independently of frequency
Low-density lipoprotein cholesterol (LDL-C) Below 80 mg/dL Catches the unfavourable lipid shift reported in the diabetes trial
High-density lipoprotein cholesterol (HDL-C) 50 to 80 mg/dL Fell alongside the LDL-C rise in the same trial
Fasting glucose 75 to 86 mg/dL Tracks the one metabolic endpoint with a positive signal
Glycated haemoglobin (HbA1c) 4.8% to 5.4% Three-month average blood sugar; less noisy than a single glucose reading
High-sensitivity C-reactive protein (hs-CRP) Below 0.8 mg/L General whole-body inflammation, the proposed downstream of the fermentation products
Faecal calprotectin Below 50 µg/g Separates functional symptoms from actual gut wall inflammation before the supplement is blamed
Hydrogen and methane breath test Negative by the testing laboratory's own criteria Screens for small intestinal bacterial overgrowth, the setting in which symptoms worsen
Waist circumference Below 94 cm in men, 80 cm in women The adiposity measure that moved in the body composition trials

Cadence: Bowel diary run continuously through the first eight weeks; bloodwork repeated at twelve weeks, then every six to twelve months if use continues.

Qualitative Assessment

  • Straining and the sense of incomplete evacuation, scored daily on a simple 0 to 10 scale
  • Bloating and abdominal distension, especially in the first two weeks while fermentation adjusts
  • Post-meal comfort after dairy, where lactose digestion is the reason for use
  • Mental clarity, since fogginess is the flag for overgrowth rather than benefit
  • Sleep quality and time taken to fall asleep
  • Frequency and duration of common respiratory infections across a full winter